Oncology

Researchers question screening guidelines for older women after findings.

Distinguishing between atypical hepatocellular carcinomas and intrahepatic cholangiocarcinoma can be difficult, but researchers identified several reliable MRI features to assist in differentiation.

If approved, glofitamab will treat the most aggressive type of non-Hodgkin lymphoma.

The findings show promising clinical activity and a favorable tolerability profile in the treatment of KRASG12C-mutated advanced colorectal cancer.

A better understanding of the pathogenesis of monoclonal gammopathy of clinical significance would help guide clinicians treating the complex condition.

This technology could facilitate equal access to value-based pathways in oncology care and optimize the individual treatment approach.

The opportunity to provide non-invasive colorectal cancer screening and education to patients is undoubtedly a role that pharmacists can fill.

The dual-action cell therapy is designed to eliminate established tumors, train the immune system to eradicate a primary tumor, and prevent recurrence.

In this special January issue covering ASH and SABCS, we have divided the publication by conference.

In 10 states, the data showed more than 26% of women had limited accessibility to mammography, primarily in the Rocky Mountains and the South.

Participants who survived Hodgkin lymphoma as children showed signs of being biologically older than their peers, with a heightened risk of cognitive problems.

The phase 2 GO29781 study showed that 80% of patients who had received at least 2 prior therapies achieved durable response rates with mosunetuzumab-axgb treatment.

The FDA's approval includes the group indication for all current and future EGFR TKIs, including erlotinib, osimertinib, and gefitinib.

HOPA DEI Committee chair Kamakshi Rao, PharmD, BCOP, FASHP, noted that on the DEI journey ahead, the oncology pharmacist should be front and center as part of the treatment team.

Calcitriol may offer protection from the harmful effects of the chemical in drinking water, analysis shows.

The protein is vitally important and could be a prognostic indicator and potential therapeutic target.

Significant advancements have changed the treatment landscape and clinical practice procedures.

From newsworthy moments to groundbreaking research, these are the most popular articles in the cholangiocarcinoma space, published on Pharmacy Times® during 2022.

An anti-cancer vaccine that is now in clinical trials shows promise as a preventative agent. However, experts are unsure when it will be widely available.

Recommendations for the management of bile duct cancer benefit authorities, patients, and physicians, but investigators say more research is needed.

The FDA granted Priority Review to both applications and set a Prescription Drug User Fee Act goal date for each application of April 21, 2023.

Targeted therapies have greatly improved patient outcomes over the past 20 years.

Trends in treatment development involve more targeted, safe, and efficacious therapies.

Lack of access to novel therapies, especially within the cancer space, initiated the road to patient navigation.

The additional indication expands its therapeutic role beyond advanced non-small cell lung cancer.

Specific immune checkpoint inhibitors added to frontline chemotherapy have transformed modern clinical practice.

Identifying how survivors adjust to their cancer may help health care providers provide tailored self-management skills.

The median progression-free survival and overall survival were 7.4 and 14.7 months, respectively, in chemotherapy-naïve patients with advanced or recurrent biliary tract cancer.